Israel - Ibrani - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

Israel - Ibrani - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

Israel - Ibrani - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 40 mg - pantoprazole - pantoprazole - short term treatment of acute duodenal ulcer. acute gastric ulcer. moderate and severe reflux esophagitis. eradication of helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing of duodenal and gastric ulcers caused by this microorganism. zollinger ellison syndrome.

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 100 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Israel - Ibrani - Ministry of Health

csl behring ltd., israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein c; protein s antigen - אבקה וממס להכנת תמיסה להזרקה - coagulation factor ii (human) 200 - 480 iu; coagulation factor vii (human) 100 - 250 iu; coagulation factor ix (human- rfixfc) 200 - 310 iu; coagulation factor x (human) 220 - 600 iu; protein c 150 - 450 iu; protein s antigen 120 - 380 iu - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - -treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Israel - Ibrani - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl.; folic acid - טבליה - folic acid 0.4 mg; ferrous as iron iii hydroxide polymaltose compl. 100 mg - ferrous amino acid complex - ferrous amino acid complex - prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.

Israel - Ibrani - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israel - Ibrani - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob